Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Latest News on TCRX

Dec 26, 2024, 7:00 AM EST - 25 days ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 4 weeks ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 6 weeks ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 6 weeks ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 7 weeks ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 2 months ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 3 months ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 29, 2024, 7:00 AM EDT - 5 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 26, 2024, 10:09 AM EDT - 5 months ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 5 months ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 7 months ago

TScan Therapeutics Announces Updates to its Board of Directors

May 30, 2024, 7:00 AM EDT - 8 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 8 months ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 9 months ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 9 months ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 9 months ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 9 months ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 9 months ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 9 months ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 9 months ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 9 months ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 9 months ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 10 months ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 10 months ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 11 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 11 months ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 11 months ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Dec 27, 2023, 7:00 PM EST - 1 year ago

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

Dec 9, 2023, 12:00 PM EST - 1 year ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 7, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Dec 4, 2023, 4:05 PM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

Dec 4, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

Nov 30, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

Nov 9, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Nov 2, 2023, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

Oct 14, 2023, 3:32 AM EDT - 1 year ago

TScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest

Sep 27, 2023, 9:06 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

Aug 29, 2023, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

Aug 10, 2023, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 6, 2023, 9:30 AM EDT - 1 year ago

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

Jun 29, 2023, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Transition of Chief Financial Officer

Jun 6, 2023, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

Jun 1, 2023, 4:10 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

Jun 1, 2023, 4:05 PM EDT - 1 year ago

Market Cap	128.09M
Revenue (ttm)	21.05M
Net Income (ttm)	-89.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-423.85%
Debt to Equity Ratio	0.13

Volume	238,500
Avg Vol	470,542
Day's Range	N/A - N/A
Shares Out	53.37M
Stochastic %K	3%
Beta	0.91
Analysts	Strong Sell
Price Target	$12.14